Eli Lilly patent expiries force revenue to fall

03-02-2015

Eli Lilly patent expiries force revenue to fall

Viorel Sima / Shutterstock.com

Pharmaceutical company Eli Lilly has reported that its US revenue in 2014 dipped by 29% compared to the previous year, laying the blame on key patents, including those for Cymbalta (duloxetine hydrochloride) and Evista (raloxifene hydrochloride), expiring.


Eli Lilly, Cymbalta, Evista, patent expiries, results

LSIPR